{"id":38249,"date":"2025-07-31T11:26:45","date_gmt":"2025-07-31T03:26:45","guid":{"rendered":"https:\/\/flcube.com\/?p=38249"},"modified":"2025-07-31T11:26:46","modified_gmt":"2025-07-31T03:26:46","slug":"gsk-reports-6-sales-growth-in-q2-2025-driven-by-specialty-medicine-and-vaccines","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38249","title":{"rendered":"GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines"},"content":{"rendered":"\n<p>UK-based GlaxoSmithKline (GSK; <a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>) released its Q2 and H1 2025 financial results. Q2 sales reached GBP 7.99 billion (USD 10.66 billion), reflecting a 6% year-on-year (YOY) growth in constant currency terms. H1 sales were up 5% YOY to GBP 15.5 billion (USD 20.7 billion).<\/p>\n\n\n\n<p><strong>Q2 Performance by Segment<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Specialty Medicine<\/strong>: Sales increased by 15% YOY to GBP 3.3 billion.<\/li>\n\n\n\n<li><strong>Vaccines<\/strong>: Sales grew by 9% to GBP 2.1 billion.<\/li>\n\n\n\n<li><strong>General Medicines<\/strong>: Sales decreased by 6% to GBP 2.6 billion.<\/li>\n<\/ul>\n\n\n\n<p><strong>Key Product Highlights<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HIV Treatments<\/strong>: Showed strong growth of +12% to GBP 1.88 billion (USD 2.5 billion), driven by long-acting injectables (LAIs).<\/li>\n\n\n\n<li><strong>Nucala (Mepolizumab)<\/strong>: Q2 sales rose 7% to GBP 498 million (USD 665 million), despite pricing pressure in the U.S. due to Medicare reforms, with stronger growth in Europe and international markets.<\/li>\n\n\n\n<li><strong>Benlysta (Belimumab)<\/strong>: Sales increased by 13% to GBP 451 million (USD 602 million).<\/li>\n\n\n\n<li><strong>Oncology Sales<\/strong>: Rose by 42% to GBP 484 million (USD 646 million), driven by Jemperli (dostarlimab), Zejula (niraparib), and Ojjaara\/Omjjara (momelotinib). Jemperli sales grew by 91% to GBP 196 million (USD 262 million).<\/li>\n\n\n\n<li><strong>Vaccines<\/strong>: Shingrix sales reached GBP 853 million (USD 1,138 million, +6%); Meningitis vaccines generated GBP 379 million (USD 506 million, +22%); RSV vaccine Arexvy grew by 13% to GBP 66 million (USD 88 million).<\/li>\n<\/ul>\n\n\n\n<p><strong>Hengrui Partnership<\/strong><br>GSK recently announced a significant partnership with China\u2019s Hengrui Medicine. The deal involves an upfront payment of USD 500 million and covers up to 12 innovative medicines, with a focus on GSK\u2019s Respiratory, Immunology &amp; Inflammation (RI&amp;I) and Oncology businesses. The first selected candidate is a potential best-in-class PDE3\/4 inhibitor (HRS-9821) for COPD treatment. GSK will hold all development and commercial rights outside the Greater China market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/q2-2025-results-announcement.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of q2-2025-results-announcement.\"><\/object><a id=\"wp-block-file--media-71ca7504-0d45-44c3-8bdb-fc356092ee2d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/q2-2025-results-announcement.pdf\">q2-2025-results-announcement<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/q2-2025-results-announcement.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-71ca7504-0d45-44c3-8bdb-fc356092ee2d\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/q2-2025-pipeline-assets-and-clinical-trials-report.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of q2-2025-pipeline-assets-and-clinical-trials-report.\"><\/object><a id=\"wp-block-file--media-c7cf5d12-9666-422c-bf77-406f6a04c277\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/q2-2025-pipeline-assets-and-clinical-trials-report.pdf\">q2-2025-pipeline-assets-and-clinical-trials-report<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/q2-2025-pipeline-assets-and-clinical-trials-report.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c7cf5d12-9666-422c-bf77-406f6a04c277\">Download<\/a><\/div>\n\n\n\n<div class=\"wp-block-file\"><a id=\"wp-block-file--media-64a41ea9-6154-4d78-9432-27fe833dfcf5\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/q2-2025-epidemiology-report.xlsx\">q2-2025-epidemiology-report<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/q2-2025-epidemiology-report.xlsx\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-64a41ea9-6154-4d78-9432-27fe833dfcf5\">Download<\/a><\/div>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>UK-based GlaxoSmithKline (GSK; NYSE: GSK) released its Q2 and H1 2025 financial results. Q2 sales&#8230;<\/p>\n","protected":false},"author":1,"featured_media":38254,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,278,184,914],"class_list":["post-38249","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based GlaxoSmithKline (GSK; NYSE: GSK) released its Q2 and H1 2025 financial results. Q2 sales reached GBP 7.99 billion (USD 10.66 billion), reflecting a 6% year-on-year (YOY) growth in constant currency terms. H1 sales were up 5% YOY to GBP 15.5 billion (USD 20.7 billion).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38249\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines\" \/>\n<meta property=\"og:description\" content=\"UK-based GlaxoSmithKline (GSK; NYSE: GSK) released its Q2 and H1 2025 financial results. Q2 sales reached GBP 7.99 billion (USD 10.66 billion), reflecting a 6% year-on-year (YOY) growth in constant currency terms. H1 sales were up 5% YOY to GBP 15.5 billion (USD 20.7 billion).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38249\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-31T03:26:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-31T03:26:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3103.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38249#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38249\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines\",\"datePublished\":\"2025-07-31T03:26:45+00:00\",\"dateModified\":\"2025-07-31T03:26:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38249\"},\"wordCount\":276,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38249#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/3103.webp\",\"keywords\":[\"Finanical Reports\",\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38249#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38249\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38249\",\"name\":\"GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38249#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38249#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/3103.webp\",\"datePublished\":\"2025-07-31T03:26:45+00:00\",\"dateModified\":\"2025-07-31T03:26:46+00:00\",\"description\":\"UK-based GlaxoSmithKline (GSK; NYSE: GSK) released its Q2 and H1 2025 financial results. Q2 sales reached GBP 7.99 billion (USD 10.66 billion), reflecting a 6% year-on-year (YOY) growth in constant currency terms. H1 sales were up 5% YOY to GBP 15.5 billion (USD 20.7 billion).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38249#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38249\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38249#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/3103.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/3103.webp\",\"width\":1080,\"height\":608,\"caption\":\"GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38249#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines - Insight, China&#039;s Pharmaceutical Industry","description":"UK-based GlaxoSmithKline (GSK; NYSE: GSK) released its Q2 and H1 2025 financial results. Q2 sales reached GBP 7.99 billion (USD 10.66 billion), reflecting a 6% year-on-year (YOY) growth in constant currency terms. H1 sales were up 5% YOY to GBP 15.5 billion (USD 20.7 billion).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38249","og_locale":"en_US","og_type":"article","og_title":"GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines","og_description":"UK-based GlaxoSmithKline (GSK; NYSE: GSK) released its Q2 and H1 2025 financial results. Q2 sales reached GBP 7.99 billion (USD 10.66 billion), reflecting a 6% year-on-year (YOY) growth in constant currency terms. H1 sales were up 5% YOY to GBP 15.5 billion (USD 20.7 billion).","og_url":"https:\/\/flcube.com\/?p=38249","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-31T03:26:45+00:00","article_modified_time":"2025-07-31T03:26:46+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3103.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38249#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38249"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines","datePublished":"2025-07-31T03:26:45+00:00","dateModified":"2025-07-31T03:26:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38249"},"wordCount":276,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38249#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3103.webp","keywords":["Finanical Reports","GlaxoSmithKline","GSK","NYSE: GSK"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38249#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38249","url":"https:\/\/flcube.com\/?p=38249","name":"GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38249#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38249#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3103.webp","datePublished":"2025-07-31T03:26:45+00:00","dateModified":"2025-07-31T03:26:46+00:00","description":"UK-based GlaxoSmithKline (GSK; NYSE: GSK) released its Q2 and H1 2025 financial results. Q2 sales reached GBP 7.99 billion (USD 10.66 billion), reflecting a 6% year-on-year (YOY) growth in constant currency terms. H1 sales were up 5% YOY to GBP 15.5 billion (USD 20.7 billion).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38249#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38249"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38249#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3103.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3103.webp","width":1080,"height":608,"caption":"GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38249#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3103.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38249"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38249\/revisions"}],"predecessor-version":[{"id":38255,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38249\/revisions\/38255"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38254"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}